Fortis Healthcare Limited has announced changes to its Board of Directors composition, with one new appointment and one resignation taking effect on December 19, 2025. The healthcare company communicated these developments to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

New Director Appointment

The Board of Directors approved the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as Additional Director (Non-Executive Non-Independent) through a circular resolution passed on December 19, 2025. The appointment became effective from December 19, 2025, at 09:01 AM (IST), following the recommendation of the company's Nomination and Remuneration Committee.

Professional Background

Mr. Shahazwan brings extensive experience to the Board, with over 25 years in investments, mergers and acquisitions, portfolio and asset management, corporate strategy, and restructuring. He currently serves as Advisor, Special Projects in UEM Group and was appointed to the Board of IHH Healthcare Berhad in March 2023.

His career highlights include:

• Head, Strategic Investments at Employees Provident Fund (EPF), overseeing investments in key portfolio companies and leading active stewardship initiatives
• Chief International Officer at Tenaga Nasional Berhad (TNB), leading international business operations and pivoting focus toward renewables and new energy opportunities
• Investment roles at Khazanah Nasional Berhad from 2005 to 2016, covering investments across Asia and Europe
• Advisory positions at Bain & Co. (Kuala Lumpur/Southeast Asia) and Temasek International Advisory (Singapore)

Director Resignation

Concurrently, Mr. Lim Tsin Lin resigned from his position as Non-Executive Non-Independent Director, effective from the close of business hours on December 19, 2025, at 01:23 PM (IST). In his resignation letter, he cited other commitments and responsibilities as the reason for his departure.

Board Relationships and Compliance

The company disclosed that Mr. Shahazwan is not related to any existing Directors of the company. However, several current Board members including Dr. Prem Kumar Nair, Mr. Dilip Kadambi, Mr. Ashok Pandit, and Dr. Keith Hsiu Chin Lim serve as nominee directors of Northern TKV Venture Pte. Ltd.

Fortis Healthcare confirmed that Mr. Shahazwan is not debarred from holding the office of Director by any order passed by SEBI or other regulatory authorities. All regulatory disclosures have been made in compliance with SEBI listing regulations and relevant master circulars.

Fortis Healthcare executed a major block trade on the National Stock Exchange (NSE), marking significant institutional trading activity in the healthcare sector. The transaction involved a substantial volume of shares at a premium price point.

Block Trade Details

The block trade encompassed 419,265 shares of Fortis Healthcare, executed at ₹885.10 per share. This pricing resulted in a total transaction value of ₹37.11 crores, indicating strong institutional interest in the healthcare company's stock.

Market Significance

Block trades typically involve large institutional investors and represent significant capital movements in the market. The execution of this trade at ₹885.10 per share demonstrates the price discovery mechanism for large volume transactions in Fortis Healthcare's stock.

The transaction size of ₹37.11 crores reflects substantial institutional participation, which often indicates confidence in the company's fundamentals and growth prospects among large investors. Such block trades are executed outside the regular market hours to minimize impact on stock price volatility.